Celgene (NASDAQ:CELG), among other biotech companies, has fallen from its record high. The company has returned negative 15% for the past year, and negative 26% from its high of $134 a share back in July 2015 compared to its Tuesday morning price of $96.89 a share. The iShares NASDAQ Biotechnology Index ETF, on the other hand, has performed worst at negative 32% for the past year. Along with leveraged commodity ETFs, the biotech sector has experienced Mr. Market’s dark side. The Standard & Poor’s 500 returned -2% in the same timeframe.
read more here http://www.gurufocus.com/news/422774/celgene-is-it-a-buy
“If you can’t beat the market, be the market.” Seth Klarman (Trades, Portfolio)
Perennial investing by Mark Y. 
Hi Mark! Im also a filipino chinese who loves reading and invests on stocks/bonds globally. Nice seeing another fil chi with the same interest 🙂
LikeLiked by 1 person
Hi Mark, nice seeing a filchi with the same interest. God bless you more on this endeavor!
LikeLiked by 1 person
Thanks Jane. I appreciate that. Patience is a must in investing especially in this environment. I would suggest you join this small group we have in Facebook (if you have FB account) and so you could also freely share your ideas (https://www.facebook.com/groups/SeekingValue/). I hope you do well also in your investments.
Mark
LikeLiked by 1 person